ARTICLE | Finance
Ebb & Flow
April 28, 2008 7:00 AM UTC
On Friday, investors savaged Isis (NASDAQ:ISIS) and dinged partner Genzyme (NASDAQ:GENZ) on news that NDA submissions for their mipomersen cholesterol-lowering drug would take longer than anticipated.
Isis fell $4.81 (29%) to $11.99, while Genzyme dipped $0.85 to $72.49. Isis, which has had a string of partnership deal announcements, has not been at this level since late August 2007...